Technology ID
TAB-4835
Tailored HIV Vaccines: Regional Strategies for Clade-Specific Protection and Treatment
E-Numbers
E-010-2011-0
Lead Inventor
Amara, Rama
Lead IC
NIAID
Co-Inventors
Moss, Bernard
Wyatt, Linda
Robinson, Harriet
ICs
NIAID
Applications
Vaccines
Therapeutics
Diagnostics
Therapeutic Areas
Infectious Disease
Immunology
Development Stages
Pre-clinical (in vivo)
Research Products
Research Equipment
Plasmids/Vectors
Antibodies
Animal Models
In this groundbreaking approach, a versatile AIDS vaccine technology is tailored to target distinct HIV clades prevalent in different regions, including Clade B for the United States, Clade AG for West Africa, and Clade C for South Africa and India. The vaccine serves a dual purpose, functioning both as a prophylactic and therapeutic solution against HIV/AIDS. Furthermore, it can be employed in synergy with DNA vaccines and the immune-boosting properties of GM-CSF to enhance the immune response. This innovative strategy offers hope for more effective and region-specific HIV prevention and treatment options, potentially revolutionizing the global fight against the virus.
Commercial Applications
This AIDS vaccine technology holds diverse applications, offering region-specific protection and treatment against HIV/AIDS by targeting different clades. Its dual-purpose design accommodates both prevention and therapy, adaptable to varying disease stages. Combined with DNA vaccines, it introduces innovative strategies for enhanced efficacy. The inclusion of GM-CSF as an adjuvant further broadens its applications, making it a versatile asset in the quest for comprehensive HIV/AIDS solutions.
Competitive Advantages
This AIDS vaccine technology offers competitive advantages through its tailored approach targeting region-specific HIV clades (e.g., Clade B, Clade AG, Clade C). Its dual prophylactic and therapeutic capabilities provide a comprehensive solution. The potential for synergy with DNA vaccines enhances efficacy, and the use of GM-CSF as an adjuvant strengthens its competitive edge, positioning it as a leading candidate in HIV vaccine research.
Licensing Contact: